Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Primary Cutaneous B-Cell Lymphomas

Written2019-07Ayad M. Al-Katib, Anwar N. Mohamed
Lymphoma Research Laboratory, Department of Medicine, Gordon H. Scott Hall for Basic Medical Sciences, Room #8229, 540 East Canfield (AMAK) and the Cytogenetics Laboratory, Department of Pathology, (ANM), Wayne State University School of Medicine, Detroit, MI 48202 USA

Abstract Primary cutaneous B-cell lymphomas (PCBCL) are a heterogeneous group of mature B-cells neoplasms that present in the skin without evidence of nodal or systemic involvement. The clinical and pathologic features of PCBCL differ significantly from the equivalent nodal lymphomas. Three main subtypes of PCBCL are recognized by the 2016 revised WHO classification. Studies have shown that PCBCLs are characterized by distinct immunophenotypic features, chromosomal aberrations and gene rearrangements which provide further support for their classification as separate entities from their nodal types.

Keywords Skin diseases, lymphoma, B-lymphocytes, diffuse large B-cell lymphoma, marginal zone lymphoma, follicle center cell lymphoma

(Note : for Links provided by Atlas : click)


ICD-Topo C420,C421,C424
Atlas_Id 1851
Note Lymphoma is classified as primary cutaneous lymphoma (PCL) when the malignant lymphocyte proliferation is limited to the skin with no involvement of lymph nodes, bone marrow or viscera at diagnosis. PCLs are the most frequent extra-nodal lymphomas, with incidence around 10 cases per million individuals per year, from which 25-30% are primary cutaneous B-cell lymphomas (PCBCL) (Kempf W et al 2014 Mar). PCBCLs are characterized by great biological and clinical variability among its various subtypes (Sokotowska-Wojdyto 2015). The classification was revolutionized by the consensus statement between the World Health Organization (WHO) and European Organization for the Research and Treatment of Cancer in 2005. The distinct cutaneous B-cell lymphoma entities are discussed here.
Currently, the CBCL classified according to WHO-EORTC classification into three main subtypes (Swerdlow 2017) which are the following:
  • Primary cutaneous follicle center lymphoma (PCFCL)
  • Primary cutaneous marginal zone lymphoma (PCMZL)
  • Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL)
    The WHO classification was updated in 2018 to include additional provisional entity, EBV-positive mucocutaneous ulcer and to recognize 2 subsets of PCMZL (Willemze 2019). Intravascular large B-cell lymphoma was also included as part of CBCL. While it has a 'cutaneous' variant (Ferreri 2004), this entity will not be discussed further in this review. It is critical to distinguish PCBCL from systemic B cell lymphomas with secondary skin involvement because the clinical behaviors, prognosis, and management differ considerably.
  • Clinics and Pathology

    Phenotype / cell stem origin Cell Origin: CBCL, by definition, is of B-cell origin. All entities express mature B-cell phenotype. Cells are positive for a variety of B-cell markers like surface immunoglobulins (sIg), pan B-cell antigens like CD19, CD20 and/or CD79b. Each entity may be associated with certain immunophenotypes as demonstrated below under Pathology. Putative normal counterpart of PCMZL is post germinal center marginal zone B-lymphocytes of secondary lymphoid follicles. PCMZL is considered a type of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). The PCFCL is thought to arise from mature germinal center cells B-cell while the PCDLBCL, leg-type arises from peripheral B-cells of post germinal center origin (Hoefnagel 2005).
    Embryonic origin The exact etiology and pathogenesis of CBCL is poorly understood. However, dysregulation of an antigen-driven response and infectious etiologies have been proposed in some cases. Dysregulation of germinal center B-cell proliferation might play a role in PCFCL. Infection by Borrelia burgdorferi has been implicated as etiological factor in PCMZL since DNA sequences of this organism were found in skin lesions of some PCMZL cases. However, such association may be geography- dependent since some studies have questioned this association (Ponzoni 2011).
    Epidemiology Approximately 25% of all non-Hodgkin lymphoma (NHL) cases will present at an extranodal site without systemic involvement. The overall incidence of primary cutaneous lymphomas in Western countries is estimated to be 0.5 to 1 case per 100,000 people annually. The PCBCLs make up approximately 25% of all primary cutaneous lymphomas, the remainder predominantly T-cell lymphomas (Swerdlow 2013). The incidence varies geographically with lower rates in some countries (Abeldano 2018). PCMZL represents an indolent type of CBCL comprising approximately 7% of PCL and approximately 25% of CBCL. In the revised WHO classification of lymphoma, PCMZL is considered under extranodal marginal zone lymphoma of MALT type (Swerdlow 2016, Swerdlow 2017). PCMZL usually presents in the fifth decade of life, although the disease has been diagnosed in children (Kempf 2014 Aug). Men are diagnosed approximately twice as often as women. Most cases occur in non-Hispanic Whites (Kempf 2014 Mar). The PCFCL is the most common PCBCL, accounting for approximately 60% of such cases (Willemze 2005, Willemzie 2019). It is primarily a disease of middle aged to older patients (median age at onset is 51) and a male to female ratio of approximately 1.5:1 (Zinzani 2006, Bradford 2009, Swerdlow 2017). PCLBCL, leg type comprises 5% of all cutaneous lymphomas and 20% of all PCBCLs. The median age at presentation is in the mid to late seventies and is more common in females than in males with a male to female ratio of 1:3-4 (Swerdlow 2017). In contrast to the previous 2 entities, PCDLBCL-leg type is an aggressive disease and is associated with poor prognosis.
    Clinics Clinically, PCL is defined as non-Hodgkin's lymphoma (NHL) presenting in the skin with no evidence of extra-cutaneous disease at time of diagnosis for 6 months following initial diagnosis (Willemze 2005). This definition requires that clinicians conduct careful staging work up according to standard guidelines (Cheson 2014) to document the absence of disease elsewhere before designation as PCL. If disease is found elsewhere, like lymph nodes or other extranodal sites, then skin involvement is secondary, and the patient is designated to have stage IV lymphoma with skin involvement. As described below, none of the CBCL types has a pathognomonic appearance skin lesions and a biopsy of representative lesion is required to establish the diagnosis.
    PCMZL manifests as solitary or multiple reddish, dome-shaped papules, nodules or erythematous plaques. The disease frequently presents in the trunk or extremities, and to a lesser extent in the head and neck area.
    PCFCL commonly presents in the scalp and forehead (Figure 1A) but can involve the trunk and limbs. Lesions can be solitary or grouped and vary from pink papules to violaceous nodules. PCFCL that presents in the trunk (Figure 1B) used to be called reticulohistiocytoma of the dorsum or Crosti lymphoma' (Berti 1988).
    PCDLBCL can be divided into 2 distinct sub-entities: PCDLBCL-leg type, and PCDLBCL-other (Paulli 2012). The leg type (LT) is commonly seen in older women and usually presents in the lower extremities although other sites of the body can be involved. The disease presents as rapidly growing solitary or multiple nodules or plaques (Figure 1C). The lesions are pink, red, bluish-red or violaceous in color. Unlike PCMZL and PCFCL, DLBCL-LT is an aggressive disease where most patients will have local recurrence and/or extracutaneous progression and poor overall survival (Grange 2007). PCDLBCL-other includes T-cell/histiocyte-rich DLBCL, plasmablastic lymphoma, intravascular large B-cell lymphoma and other types that are distinct from PCDLBCL-LT.
    Figure 1: A: PCFCL in forehead and scalp; B: PCFCL in upper back. Skin lesions range between plaques, papules and tumor nodules which are reddish in color. C: PCDLBCL in left leg. Multiple plaque lesions
    Pathology The diagnosis is established by performing a biopsy of the skin lesions, through histological examinations, complemented by immunophenotypic and genotypic studies (Swerdlow 2013; Kempf 2014). Histologically, three growth patterns have been recognized in PCFCL: follicular, diffuse or follicular and diffuse; the diffuse pattern is most frequent (Figure 2A). Cells are small lymphocytes (centrocytes) with few large cells (centroblasts or immunoblasts) (Figure 2B). Immunohistochemical stain typically shows the lymphocytic infiltrate to be positive for CD20 and BCL6 but is generally negative for CD10 and BCL2 (Figure 4C-F). Some cases may express BCL2 in a minority of malignant cells but staining is usually faint and is weaker than admixed reactive T-cells. CD10 may also be positive in some cases of follicular growth pattern but is negative in cases of diffuse growth pattern. Strong expression of BCL2 and CD10 should raise suspicion that skin involvement is secondary to a nodal follicular lymphoma rather than PCFCL. T-cell markers and CD30 are negative; however, CD3 may stain reactive T-cells which may be numerous.
    Histopathologic findings of PCMZL include a nodular or diffuse nonepidermotropic infiltrate composed of small to medium-size lymphoid cells (Figure 3A). The nuclei are indented, and cells have abundant cytoplasm. Lymphoid cell infiltrate can be admixed with various number of plasma cells and reactive T-cells. Asian cases with PCMZL were reported to show tissue eosinophilia in tumor specimens, a feature not found in cases from Germany or United States (Takino 2008). Immunophenotypically, PCMZL tumor cells express B-cell markers like CD20 (Figure 3B), and CD79a. CD3 highlights reactive T-cells which sometimes are present in larger numbers than the malignant B-cells (Figure 3C). In such cases, it is important to document B-cell monoclonality which can be demonstrated using IHC techniques like in situ hybridization for immunoglobulin light chain staining. Malignant B-cells are negative for germinal center markers like CD10 and BCL6 (Figure 3D).
    PCDLBCL, LT is characterized histologically by diffuse infiltrate covering the entire dermis but usually spares a thin subepidermal grenz zone and the epidermis (Figure 4A). Tumor cell infiltrate destroys adnexal structures and extends to subcutaneous tissue. As the name implies, cells are large B-cells (also referred to as centroblasts or immunoblasts) (Figure 4B). The immunophenotype of tumor cells typically is positive for CD19, CD20 (Figure 4C), CD79a, BCL2, and MUM1 (Figure 4D). Cells are usually negative for CD3 (Figure 4E), CD5, CD21, CD138, CD10, and cyclin D1. Cell proliferation is high (Figure 4F). Strong expression of BCL2 and MUM1 in PCDLBCL, LT helps distinguish this entity from diffuse type PCFCL which is negative for these 2 markers.
    Figure 2: A, Skin biopsy of a patient with PCFCL. H & E stain; B, PCFCL, diffuse growth pattern. H & E; C, PCFCL, Immunohistochemical (IHC) stain of CD20 showing strong positive staining of lymphocytic infiltrate; D, PCFCL, IHC showing diffusely positive staining for BCL6; E, PCFCL, IHC showing positive BCL2 stain in a pattern similar to CD3 staining; 4F: PCFCL, IHC showing negative stain for CD10
    Figure 3; A: PCMZL, Skin biopsy showing deep dermal lymphocytic infiltrate; B: PCMZL. CD20 stain; C: PCMZL. CD3 stain showing abundant reactive T-cells; D: PCMZL. BCL6 stain, negative
    Figure 4; A: PCDLBCL, LT. H & E stain, low power showing diffuse infiltration of the dermis with sparing of the epidermis and subepidermal layers; B: PCDLBC6BL, LT. Large cells (centroblasts) with irregular vesicular nuclei and few apoptotic cells; C: PCDLBCL, LT. Strongly positive CD20 membrane stain; D: PCDLBCL, LT. MUM1 stain. Most of the large lymphoma cells are positive. E: PCDLBCL, LT. CD3 stain showing few reactive T-cells. The large cells are negative. F: PCDLBCL, LT. Ki 67. More than 90% of cells show positive nuclear stain.
    Treatment The choice of therapy of CBCL relies on correct histopathologic classification and the exclusion of systemic disease. The European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) have published consensus recommendations for the management of CBCL (Sneff 2008). For localized PFCL and PCMZL, the disease is managed by local therapy, such as radiation or surgical excision. Observation is appropriate for asymptomatic multifocal presentation of these categories given their indolent nature. However, for symptomatic, progressive or relapsed disease, a variety of systemic therapies are available. The simplest is anti-CD20 (rituximab) monotherapy in a standard dose/schedule.
    Prognosis Subclassification and the extent of cutaneous involvement were identified as the most relevant prognostic factors in CBCL (Zinzani 2006). PCFCL and PCMZL are indolent types of cutaneous lymphoma with excellent prognosis. The 5 year survival rate is 90-95%. However, like their nodal counterparts, they have tendency to recur in up to 40% of cases but dissemination to extracutaneous sites is rare (Chan 2016). Both PCFCL and PCMZL can transform to DLBCL with a more aggressive behavior. The PCDLBCL, LT on the other hand is an aggressive disease with a 5 year survival of 20-50%. Mutation of the Myeloid Differentiation (MYD88) Primary Response gene (L265P) is frequently found in PCDLBCL, LT and is associated with inferior prognosis (Pham-Ledard 2014).


    Molecular study of immunoglobulin genes rearrangement is detected in all subtypes that are valuable to document clonality and differentiate PCBCL from pseudolymphomas. Until recently, cytogenetic studies had limited value in the diagnosis of PCBCL, since recurrent chromosomal and molecular alterations were not well characterized. Approximately 25% of PCMZLs demonstrate the t(14;18) (IGH/MALT1) translocation. The t(11;18) and t(3;14)orted in 7% and 10% of PCMZLs, respectively, whereas the t(1;14) translocation has not been identified in PCMZL (Abdul-Wahab, 2014). MYD88 mutations have been found in 50% of non-class-switched cases of PCMZL, but not in class-switched cases (Wobser 2017). Recurrent mutations in FAS were found in 24 of 38 (63%) patients with PCMZL (Maurus 2018).The overexpression of microRNAs MIR 155 and MIR150 is another molecular feature unique to PCMZL, and this feature may also predict longer progression-free survival.
    On the contrary, the PCDLBCL, LT shows many genetic similarities with diffuse large B cell lymphomas arising at other sites. Interphase FISH analysis frequently shows translocation involving MYC/8q24, BCL6/3q27 and IGH/14q32 genes in PCDLBCL, LT but not in patients with a PCFCL (Hallermann 2004 July). Comparative genomic hybridization (CGH), using microarrays and subsequently confirmed by FISH analysis showed that most of PCDLBCL, LT cases had chromosomal aberrations including gains in chromosomes 1, 2, 3, 7, and 12, losses in 6q, 13, 14, and 18q (Dijkman 2006). In contrast, PCFCL had fewer imbalances and lacked translocations affecting the IGH locus (Hallermann June 2004). Most PCFCL do not exhibit t(14;18)(q32;q21) that determines BCL2/IGH rearrangement and features of nodal follicular lymphoma (Abdul-Wahab 2014). The most recurrent alterations in PCFCL were high-level DNA amplifications at 2p16.1 (63%) and deletion of chromosome 14q32.33 (68%). FISH analysis confirmed REL amplification in patients with gains at 2p16.1. The same study showed that PCDLBCL, LT have a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL2 and MALT1 genes as confirmed by FISH. This may explain the strong BCL2 expression in these cases although lacking t(14;18) (BCL2/IGH) translocation. Recurrent homozygous DNA deletions in region 9p21.3 which contains CDKN2A, CDKN2B and NSG-x genes are found in 67% of PCDLBCL, LT cases but not in any of the PCFCL patients (Belaud-Rotureau 2008). In addition, some PCDLBCL, LT (17%) had a complete hypermethylation of CDKN2A gene promoter. In contrast, deletions of chromosome 9p21.3 containing the CDKN2A and CDKN2B gene loci, and MYD88 mutations are not or only rarely found in PCFCL. In conclusion, these studies clearly demonstrate distinct chromosomal and genomic aberrations in PCFCL and PCDLBCL, LT which provides further support for their categorization in the WHO-EORTC classification as separate entities. Finally, loss of chromosome 9p21.3 might prove to be an important prognostic marker in PCDLBCL, LT associated with inferior outcome (Sneff 2009) although confirmation on a larger group of patients is required. PCFCL shows the gene expression profile of germinal center-like large B cell lymphomas, and often shows amplifications of the REL gene (Hoefnagel 2005). Deletion of chromosome 14q32.33 has been also reported in PCFCL (Dijkman 2006).

    To be noted

    Acknowledgement: The authors wish to thank Drs. Ali Gabali and Feras Zaiem, Department of Pathology, Wayne State University School of Medicine for providing the pathology images; The Wayne and Joan Webber Foundation and The Birdseye Fund for Lymphoma Research for financial support


    Chromosomal anomalies in primary cutaneous follicle center cell lymphoma do not portend a poor prognosis
    Abdul-Wahab A, Tang SY, Robson A, Morris S, Agar N, Wain EM, Child F, Scarisbrick J, Neat M, Whittaker S
    J Am Acad Dermatol 2014 Jun;70(6):1010-20
    PMID 24679486
    Primary cutaneous lymphoma in Argentina: a report of a nationwide study of 416 patients
    Abeldaño A, Enz P, Maskin M, Cervini AB, Torres N, Acosta AC, Narbaitz M, Vanzulli S, Orentrajch M, Villareal MA, Garcia Pazos ML, Arias M, Zambrano Franco EA, Fontana MI, Chuit R
    Int J Dermatol 2019 Apr;58(4):449-455
    PMID 30294921
    Inactivation of p16INK4a/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas
    Belaud-Rotureau MA, Marietta V, Vergier B, Mainhaguiet G, Turmo M, Idrissi Y, Ferrer J, Beylot-Barry M, Dubus P, Merlio JP
    Virchows Arch 2008 Jun;452(6):607-20
    PMID 18311490
    Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases
    Bradford PT, Devesa SS, Anderson WF, Toro JR
    Blood 2009 May 21;113(21):5064-73
    PMID 19279331
    Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma
    Cerroni L, Zöchling N, Pütz B, Kerl H
    J Cutan Pathol 1997 Sep;24(8):457-61
    PMID 9331890
    Primary cutaneous B-cell lymphoma: systemic spread is rare while cutaneous relapses and secondary malignancies are frequent
    Chan SA, Shah F, Chaganti S, Stevens A, Amel-Kashipaz R, Vydianath B, Scarisbrick JJ
    Br J Dermatol 2017 Jul;177(1):287-289
    PMID 27641754
    Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
    Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula sea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute
    J Clin Oncol 2014 Sep 20;32(27):3059-68
    PMID 25113753
    Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma
    Dijkman R, Tensen CP, Jordanova ES, Knijnenburg J, Hoefnagel JJ, Mulder AA, Rosenberg C, Raap AK, Willemze R, Szuhai K, Vermeer MH
    J Clin Oncol 2006 Jan 10;24(2):296-305
    PMID 16330669
    Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'
    Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, Zucca E, Rossi G, López-Guillermo A, Pavlovsky MA, Geerts ML, Candoni A, Lestani M, Asioli S, Milani M, Piris MA, Pileri S, Facchetti F, Cavalli F, Ponzoni M; International Extranodal Lymphoma Study Group (IELSG)
    Br J Haematol 2004 Oct;127(2):173-83
    PMID 15461623
    Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases
    Grange F, Beylot-Barry M, Courville P, Maubec E, Bagot M, Vergier B, Souteyrand P, Machet L, Dalac S, Esteve E, Templier I, Delaporte E, Avril MF, Robert C, Dalle S, Laroche L, Delaunay M, Joly P, Wechsler J, Petrella T
    Arch Dermatol 2007 Sep;143(9):1144-50
    PMID 17875875
    Chromosomal aberration patterns differ in subtypes of primary cutaneous B cell lymphomas
    Hallermann C, Kaune KM, Siebert R, Vermeer MH, Tensen CP, Willemze R, Gunawan B, Bertsch HP, Neumann C
    J Invest Dermatol 2004 Jun;122(6):1495-502
    PMID 15175042
    Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling
    Hoefnagel JJ, Dijkman R, Basso K, Jansen PM, Hallermann C, Willemze R, Tensen CP, Vermeer MH
    Blood 2005 May 1;105(9):3671-8
    PMID 15308563
    Primary cutaneous marginal zone lymphoma in children: a report of 3 cases and review of the literature
    Kempf W, Kazakov DV, Buechner SA, Graf M, Zettl A, Zimmermann DR, Tinguely M
    Am J Dermatopathol 2014 Aug;36(8):661-6
    PMID 24698939
    Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma
    Maurus K, Appenzeller S, Roth S, Kuper J, Rost S, Meierjohann S, Arampatzi P, Goebeler M, Rosenwald A, Geissinger E, Wobser M
    J Invest Dermatol 2018 Jul;138(7):1573-1581
    PMID 29481902
    Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg-type and other: an update on morphology and treatment
    Paulli M, Lucioni M, Maffi A, Croci GA, Nicola M, Berti E
    G Ital Dermatol Venereol 2012 Dec;147(6):589-602
    PMID 23149705
    High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type
    Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, Martinez F, Cappellen D, Merlio JP, Grange F
    JAMA Dermatol 2014 Nov;150(11):1173-9
    PMID 25055137
    Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas.
    Ponzoni M, Ferreri AJM, Mappa S et al.
    The Oncologist. 2011; 16:1528-1588.
    European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas
    Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R; European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma
    Blood 2008 Sep 1;112(5):1600-9
    PMID 18567836
    Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type
    Senff NJ, Zoutman WH, Vermeer MH, Assaf C, Berti E, Cerroni L, Espinet B, de Misa Cabrera RF, Geerts ML, Kempf W, Mitchell TJ, Paulli M, Petrella T, Pimpinelli N, Santucci M, Whittaker SJ, Willemze R, Tensen CP
    J Invest Dermatol 2009 May;129(5):1149-55
    PMID 19020554
    Primary cutaneous lymphomas: diagnosis and treatment
    Sokońowska-Wojdyńo M, Olek-Hrab K, Ruckemann-Dziurdzińska K
    Postepy Dermatol Alergol 2015 Oct;32(5):368-83
    PMID 26759546
    The 2016 revision of the World Health Organization classification of lymphoid neoplasms
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES
    Blood 2016 May 19;127(20):2375-90
    PMID 26980727
    Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States
    Takino H, Li C, Hu S, Kuo TT, Geissinger E, Muller-Hermelink HK, Kim B, Swerdlow SH, Inagaki H
    Mod Pathol 2008 Dec;21(12):1517-26
    PMID 18820662
    WHO-EORTC classification for cutaneous lymphomas
    Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ
    Blood 2005 May 15;105(10):3768-85
    PMID 15692063
    Myeloid differentiation primary response 88 mutations in a distinct type of cutaneous marginal-zone lymphoma with a nonclass-switched immunoglobulin M immunophenotype
    Wobser M, Maurus K, Roth S, Appenzeller S, Weyandt G, Goebeler M, Rosenwald A, Geissinger E
    Br J Dermatol 2017 Aug;177(2):564-566
    PMID 27861728
    Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas
    Zinzani PL, Quaglino P, Pimpinelli N, Berti E, Baliva G, Rupoli S, Martelli M, Alaibac M, Borroni G, Chimenti S, Alterini R, Alinari L, Fierro MT, Cappello N, Pileri A, Soligo D, Paulli M, Pileri S, Santucci M, Bernengo MG; Italian Study Group for Cutaneous Lymphomas
    J Clin Oncol 2006 Mar 20;24(9):1376-82
    PMID 16492713


    This paper should be referenced as such :
    Ayad M Al-Katib, Anwar N Mohamed
    Primary Cutaneous B-Cell Lymphomas
    Atlas Genet Cytogenet Oncol Haematol. 2020;24(05):201-207.
    Free journal version : [ pdf ]   [ DOI ]
    On line version :

    External links

    arrayMap (UZH-SIB Zurich)[select an item]
    REVIEW articlesautomatic search in PubMed
    Last year articlesautomatic search in PubMed
    All articlesautomatic search in PubMed

    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Fri Oct 8 16:35:56 CEST 2021

    Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us